SCHEMBL2832871

SCHEMBL2832871

C=COC(=O)c1ccccc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.52
CES1 P23141 2/20 0.52
ALDH1A1 P00352 3/20 0.48
ALOX15 P16050 1/20 0.48
KMT2A Q03164 4/20 0.45
GAA P10253 1/20 0.44
MEN1 O00255 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP3A4 P08684 1/20 0.43
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
PTPN1 P18031 1/20 0.41
ERCC5 P28715 1/20 0.41
FEN1 P39748 1/20 0.41
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
ADRB2 P07550 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15175 0.86 CYP3A4 (0.55) ALDH1A1ALOX15TDP1CYP3A4NPC1
Ethylene SCHEMBL29113890 0.84 CYP3A4 (0.53) ALDH1A1ALOX15TDP1CYP3A4NPC1
SCHEMBL9630706 0.82 CES2 (0.54) CES2CES1ALDH1A1ALOX15KMT2A
SCHEMBL29197935 0.80 CYP3A4 (0.50) ALDH1A1ALOX15TDP1CYP3A4NPC1
SCHEMBL19506917 0.80 CYP3A4 (0.46) ALDH1A1ALOX15CYP3A4MAPTLMNA
SCHEMBL220576 0.78 ALDH1A1 (0.56) ALDH1A1ALOX15KMT2ATDP1CYP3A4
SCHEMBL2834918 0.78 CES2 (0.50) CES2CES1KMT2AMEN1TDP1
Acetic Acid SCHEMBL27451410 0.78 CYP3A4 (0.48) ALDH1A1ALOX15TDP1CYP3A4ESR1
SCHEMBL194863 0.78 TSHR (0.57) ALDH1A1ALOX15KMT2AGAATDP1
SCHEMBL2834785 0.78 CES2 (0.55) CES2CES1ALDH1A1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 CES2 87/4885CES1 994/4885ALDH1A1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.